Results 161 to 170 of about 320,078 (208)
Harmonisation of Low-Density Lipoprotein Cholesterol Results Obtained with Different Direct Methods: A Study Based on an External Quality Assessment Program. [PDF]
J Clin MedĆwiklińska A, Fijałkowska A.
europepmc +1 more source
Correction to: Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. [PDF]
Eur Heart Jeuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Laboratory, 2017
Malondialdehyde low-density lipoprotein (MDA-LDL) is a major form of oxidized LDL and considered to be more atherogenic than LDL. Information on major determinants of MDA-LDL and their association in subjects who are not under treatment for diabetes mellitus and dyslipidemia is limited.This study included 778 Japanese subjects who were not taking ...
Kengo, Moriyama, Eiko, Takahashi
openaire +2 more sources
Malondialdehyde low-density lipoprotein (MDA-LDL) is a major form of oxidized LDL and considered to be more atherogenic than LDL. Information on major determinants of MDA-LDL and their association in subjects who are not under treatment for diabetes mellitus and dyslipidemia is limited.This study included 778 Japanese subjects who were not taking ...
Kengo, Moriyama, Eiko, Takahashi
openaire +2 more sources
Low-Density Lipoprotein Cholesterol in Subclinical Hypothyroidism
Thyroid, 2000The significance of subclinical hypothyroidism in regard to ensuing hyperlipidemia remains unclear. Because an unfavorable lipid profile would provide a possible explanation for the reported association of coronary-heart disease with this syndrome, we have evaluated the relationship of thyrotropin (TSH) with total cholesterol, low-density-lipoprotein ...
H, Vierhapper +4 more
openaire +2 more sources
Reaching low density lipoprotein cholesterol targets
Current Medical Research and Opinion, 2014Cardiovascular disease is a major health problem and within the leading causes of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is strongly associated with the development and progression of cardiovascular disease and is among the main targets of lipid lowering therapy.
Christos V, Rizos +2 more
openaire +2 more sources
Cyclosporine, Low-Density Lipoprotein, and Cholesterol
Mayo Clinic Proceedings, 1988Lipoproteins are known to be able to transport a variety of drugs. This report suggests that low-density lipoprotein not only functions as an important carrier of cyclosporine in plasma but also facilitates transport of cyclosporine across the cell membrane by means of the low-density lipoprotein receptor. Such a mechanism would explain (1) the similar
openaire +2 more sources
Reliability of Calculated Low-Density Lipoprotein Cholesterol
The American Journal of Cardiology, 2015Aggressive low-density lipoprotein cholesterol (LDL-C)-lowering strategies are recommended for prevention of cardiovascular events in high-risk populations. Guidelines recommend a 30% to 50% reduction in at-risk patients even when LDL-C concentrations are between 70 and 130 mg/dl (1.8 to 3.4 mmol/L).
Jeffrey W, Meeusen +4 more
openaire +2 more sources
Direct testing for low-density lipoprotein cholesterol
The American Journal of Cardiology, 19956. Ismen S. Olsen K, Jacohscn E. IGclscn H, S&en A. Pietensen A. Jensen 0. Pedenen I-‘, Waahcn J. Kehlet H. Hansen J. Dalgaard P. Nyboe J. Predictmu of cardiac risk in non-cardiac surgery. Lur f&w? J I9R7:8:179 18.5. 7. Ashmn C, Pewson Ii. Wray N, Kiefe C. Dunn J. Wu 1.. Thomas J.
openaire +2 more sources
Update on low-density lipoprotein cholesterol quantification
Current Opinion in Lipidology, 2019Purpose of review β-Quantification is considered the reference measurement procedure for low-density lipoprotein cholesterol (LDL-C). However, this technique is time-consuming and thus is inappropriate for routine clinical practice. Therefore, the Friedewald equation or homogeneous assays have been widely utilized.
openaire +2 more sources
Alirocumab for low-density Lipoprotein Cholesterol Lowering
Future Cardiology, 2018Ischemic heart disease and stroke are the leading causes of death in the world currently. Both of these conditions are primarily caused by atherosclerosis, the underlying pathophysiology of which is the deposition of lipid, specifically low-density lipoprotein cholesterol (LDL-C) within the arterial bed. PCSK9, is a proteolytic enzyme, which indirectly
openaire +2 more sources